New cancer drug trial targets specific protein in advanced tumors
NCT ID NCT07083323
Summary
This study is testing a new drug called HY05350 for people with advanced solid tumors that have a specific protein called MSLN. The first part checks the drug's safety and finds the right dose, while the second part looks at how well it shrinks tumors. It's for adults whose cancer has continued to grow despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact
Conditions
Explore the condition pages connected to this study.